JP6472746B2 - 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 - Google Patents

抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 Download PDF

Info

Publication number
JP6472746B2
JP6472746B2 JP2015509208A JP2015509208A JP6472746B2 JP 6472746 B2 JP6472746 B2 JP 6472746B2 JP 2015509208 A JP2015509208 A JP 2015509208A JP 2015509208 A JP2015509208 A JP 2015509208A JP 6472746 B2 JP6472746 B2 JP 6472746B2
Authority
JP
Japan
Prior art keywords
gcc
antibody
antibody molecule
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015509208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516985A5 (OSRAM
JP2015516985A (ja
Inventor
ヘレン アリソン フランク，
ヘレン アリソン フランク，
アリス エー． マクドナルド，
アリス エー． マクドナルド，
テレサ エル． オキーフ，
テレサ エル． オキーフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6472746(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2015516985A publication Critical patent/JP2015516985A/ja
Publication of JP2015516985A5 publication Critical patent/JP2015516985A5/ja
Application granted granted Critical
Publication of JP6472746B2 publication Critical patent/JP6472746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
JP2015509208A 2012-04-27 2013-04-27 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 Active JP6472746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27
US61/639,376 2012-04-27
PCT/US2013/038542 WO2013163633A1 (en) 2012-04-27 2013-04-27 Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017087084A Division JP6517267B2 (ja) 2012-04-27 2017-04-26 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用

Publications (3)

Publication Number Publication Date
JP2015516985A JP2015516985A (ja) 2015-06-18
JP2015516985A5 JP2015516985A5 (OSRAM) 2016-06-16
JP6472746B2 true JP6472746B2 (ja) 2019-02-20

Family

ID=49477498

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015509208A Active JP6472746B2 (ja) 2012-04-27 2013-04-27 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用
JP2017087084A Active JP6517267B2 (ja) 2012-04-27 2017-04-26 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017087084A Active JP6517267B2 (ja) 2012-04-27 2017-04-26 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用

Country Status (41)

Country Link
US (3) US9000129B2 (OSRAM)
EP (1) EP2841575B1 (OSRAM)
JP (2) JP6472746B2 (OSRAM)
KR (1) KR102046435B1 (OSRAM)
CN (1) CN104395470B (OSRAM)
AR (1) AR090884A1 (OSRAM)
AU (1) AU2013251312B2 (OSRAM)
CA (1) CA2871614C (OSRAM)
CL (1) CL2014002911A1 (OSRAM)
CO (1) CO7280144A2 (OSRAM)
CR (1) CR20140497A (OSRAM)
CY (1) CY1122557T1 (OSRAM)
DK (1) DK2841575T3 (OSRAM)
DO (1) DOP2014000242A (OSRAM)
EA (1) EA034689B1 (OSRAM)
EC (1) ECSP14028523A (OSRAM)
ES (1) ES2749181T3 (OSRAM)
GE (1) GEP201706737B (OSRAM)
HR (1) HRP20191690T1 (OSRAM)
HU (1) HUE046404T2 (OSRAM)
IL (1) IL235307B (OSRAM)
LT (1) LT2841575T (OSRAM)
MA (1) MA37569B1 (OSRAM)
ME (1) ME03560B (OSRAM)
MX (1) MX362020B (OSRAM)
MY (1) MY188442A (OSRAM)
NZ (1) NZ701601A (OSRAM)
PE (1) PE20142322A1 (OSRAM)
PH (1) PH12014502399B1 (OSRAM)
PL (1) PL2841575T3 (OSRAM)
PT (1) PT2841575T (OSRAM)
RS (1) RS59370B1 (OSRAM)
SA (1) SA113340502B1 (OSRAM)
SG (1) SG11201406855TA (OSRAM)
SI (1) SI2841575T1 (OSRAM)
SM (1) SMT201900536T1 (OSRAM)
TN (1) TN2014000454A1 (OSRAM)
TW (1) TWI631137B (OSRAM)
UA (1) UA117910C2 (OSRAM)
WO (1) WO2013163633A1 (OSRAM)
ZA (1) ZA201407723B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
CA2928043A1 (en) * 2013-10-21 2015-04-30 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
ES2754282T3 (es) 2014-02-14 2020-04-16 Bioventures Llc Aductos acetaminofén proteína y procedimientos de uso de los mismos
US10570216B2 (en) 2014-12-03 2020-02-25 Bioventures, Llc Anti-acetaminophen antibodies and acetaminophen protein adducts
WO2017054089A1 (en) 2015-10-01 2017-04-06 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
AU2017375631B2 (en) * 2016-12-12 2023-06-15 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
JP7197584B2 (ja) * 2017-12-06 2022-12-27 ベンタナ メディカル システムズ， インコーポレイテッド デジタル病理学分析結果の格納および読み出し方法
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
WO2021205325A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
BR112023011658A2 (pt) * 2020-12-17 2023-10-17 Parasol Biotech Ltd Anticorpo de domínio único anti-gucy2c (sdab), receptor de antígeno quimérico (car), ácido nucleico isolado, vetor, célula efetora imune manipulada, composição farmacêutica e método de tratamento de uma doença ou distúrbio em um sujeito
EP4299594A4 (en) * 2021-04-07 2025-01-15 Lg Chem, Ltd. GUCY2C-BINDING POLYPEPTIDE AND USES THEREOF
AU2023349140A1 (en) * 2022-09-28 2025-04-03 Legend Biotech Ireland Limited Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
KR20250099224A (ko) 2022-11-01 2025-07-01 하이델베르크 파마 리서치 게엠베하 항-gucy2c 항체 및 이의 용도
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
WO2025061149A1 (zh) * 2023-09-21 2025-03-27 南京传奇生物科技有限公司 抗gcc抗体、嵌合抗原受体及其用途
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
CN120965861A (zh) * 2025-10-22 2025-11-18 杭州博茵生物技术有限公司 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
ATE259648T1 (de) 1993-10-26 2004-03-15 Univ Jefferson Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
EP0951475B1 (en) 1996-05-03 2003-07-16 Thomas Jefferson University Metastatic colorectal cancer vaccine
US6602659B1 (en) 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2001073131A1 (en) 2000-03-27 2001-10-04 Thomas Jefferson University High specificity marker detection
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN101928343B (zh) 2001-01-26 2014-09-17 英希比泰克斯公司 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
PT1379224E (pt) 2001-03-29 2009-10-22 Synergy Pharmaceuticals Inc Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese
US7358054B2 (en) 2001-04-13 2008-04-15 Biogen Idec Ma Inc. Antibodies to VLA-1
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
WO2004024750A2 (en) 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1781339B1 (en) 2004-06-25 2013-12-25 Thomas Jefferson University Guanylyl cyclase C ligands
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
HUE029649T2 (en) * 2007-08-10 2017-02-28 Janssen Biotech Inc Immunoglobulin cleavage fragments as disease indicators and preparations for detecting and binding such fragments
US7988967B2 (en) 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
NZ628598A (en) * 2007-11-30 2016-09-30 Genentech Inc Vegf polymorphisms and anti-angiogenesis therapy
US20110195415A1 (en) 2008-05-13 2011-08-11 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
JP2012510295A (ja) * 2008-12-03 2012-05-10 ベーリンガー インゲルハイム ファーマスーティカルズ アイエヌシー． グアニル酸シクラーゼ受容体に対する抗体
EP2881402B1 (en) * 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
CN102333887B (zh) 2009-02-25 2014-04-02 戴格努生命科学公司 用于检测gi癌转移的方法
WO2010104035A1 (ja) * 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
CA2801729A1 (en) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions for and methods of activating guanylyl cyclase c
EP3444333A1 (en) 2009-10-22 2019-02-20 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
AU2011288354A1 (en) * 2010-08-13 2013-01-24 F. Hoffmann-La Roche Ag Neuropilin as a biomarker for bevacizumab combination therapies
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
JP2016511257A (ja) * 2013-02-28 2016-04-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与

Also Published As

Publication number Publication date
ME03560B (me) 2020-07-20
JP2017131245A (ja) 2017-08-03
SA113340502B1 (ar) 2015-09-17
HK1208049A1 (en) 2016-02-19
PL2841575T3 (pl) 2020-01-31
NZ701601A (en) 2016-09-30
US9000129B2 (en) 2015-04-07
RS59370B1 (sr) 2019-11-29
PE20142322A1 (es) 2015-01-25
US20160130344A1 (en) 2016-05-12
CN104395470B (zh) 2018-02-06
CN104395470A (zh) 2015-03-04
EP2841575B1 (en) 2019-06-26
CO7280144A2 (es) 2015-05-29
AU2013251312B2 (en) 2018-03-22
IL235307B (en) 2019-07-31
IL235307A0 (en) 2014-12-31
PT2841575T (pt) 2019-10-11
CA2871614A1 (en) 2013-10-31
SMT201900536T1 (it) 2019-11-13
AU2013251312A1 (en) 2014-10-30
US9273146B1 (en) 2016-03-01
GEP201706737B (en) 2017-09-25
JP2015516985A (ja) 2015-06-18
TN2014000454A1 (en) 2016-03-30
PH12014502399B1 (en) 2022-04-22
KR20150004882A (ko) 2015-01-13
EA201491977A1 (ru) 2015-04-30
EA034689B1 (ru) 2020-03-06
US20130287783A1 (en) 2013-10-31
CA2871614C (en) 2021-08-31
CY1122557T1 (el) 2021-01-27
DOP2014000242A (es) 2014-11-30
HRP20191690T1 (hr) 2019-12-27
ECSP14028523A (es) 2015-09-30
HUE046404T2 (hu) 2020-02-28
UA117910C2 (uk) 2018-10-25
CL2014002911A1 (es) 2015-01-30
BR112014026742A2 (pt) 2017-07-11
KR102046435B1 (ko) 2019-11-19
AR090884A1 (es) 2014-12-10
MX2014013081A (es) 2015-01-12
LT2841575T (lt) 2019-10-10
SG11201406855TA (en) 2014-11-27
CR20140497A (es) 2015-02-10
ZA201407723B (en) 2019-01-30
TWI631137B (zh) 2018-08-01
PH12014502399A1 (en) 2014-12-22
EP2841575A1 (en) 2015-03-04
EP2841575A4 (en) 2016-06-15
WO2013163633A1 (en) 2013-10-31
SI2841575T1 (sl) 2019-11-29
DK2841575T3 (da) 2019-09-23
ES2749181T3 (es) 2020-03-19
JP6517267B2 (ja) 2019-05-22
MA37569B1 (fr) 2020-08-31
TW201348258A (zh) 2013-12-01
MY188442A (en) 2021-12-09
MX362020B (es) 2019-01-04

Similar Documents

Publication Publication Date Title
JP6472746B2 (ja) 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用
US9662405B2 (en) Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody
US10941211B2 (en) Anti-GCC antibody molecules and related compositions and methods
BR112014026742B1 (pt) Moléculas de anticorpo anti-gcc, sequências ácido nucleico, vetor, método de produção uma molécula de anticorpo e usos de uma molécula de anticorpo anti-gcc, kit e mistura de reação
HK1208049B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
HK1173961B (en) Anti-gcc antibody molecules and related compositions and methods
HK1173961A (en) Anti-gcc antibody molecules and related compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180112

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190123

R150 Certificate of patent or registration of utility model

Ref document number: 6472746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250